Smart & Biggar successfully represented Boehringer Ingelheim in a s. 6(1) action under the Patented Medicines (Notice of Compliance) Regulations regarding the use of nintedanib in the prevention or treatment of idiopathic pulmonary fibrosis.
Read more about this case via our article "Boehringer Ingelheim succeeds in nintedanib PMNOC action against JAMP".
Client Success
-
Nova Chemicals Corporation v Dow Chemical Company
2022 SCC 43Smart & Biggar successfully represented Dow Chemical before the Supreme Court of Canada, affirming the largest reported Canadian patent infringement award in history including the first time that ...Read More -
Tekna Plasma Systems Inc v AP&C Advanced Powders & Coatings Inc
2024 FC 871Smart & Biggar successfully represented Tekna Plasma Systems (Tekna), the plaintiff in this action.Read More -
McCain Foods Limited v J.R. Simplot Company
2025 FC 1078Smart & Biggar represented J.R. Simplot Company (Simplot), the Defendant in this action.Read More